Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcutis Biotherapeutics Inc ARQT

Healthcare Biotechnology
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment... see more

Recent & Breaking News (NDAQ:ARQT)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 1 day ago

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

GlobeNewswire 5 days ago

Arcutis Appoints David Topper as Chief Financial Officer

GlobeNewswire April 10, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 5, 2024

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

GlobeNewswire April 1, 2024

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire March 28, 2024

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

GlobeNewswire March 11, 2024

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

GlobeNewswire March 10, 2024

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

GlobeNewswire March 9, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 5, 2024

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

GlobeNewswire March 4, 2024

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

GlobeNewswire March 4, 2024

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 29, 2024

Arcutis Announces Pricing of $150 Million Public Offering

GlobeNewswire February 28, 2024

Arcutis Announces Proposed Public Offering

GlobeNewswire February 28, 2024

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

GlobeNewswire February 28, 2024

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire February 27, 2024

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 16, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 6, 2024

Arcutis to Present at the Guggenheim Healthcare Talks - 6th Annual Biotechnology Conference

GlobeNewswire January 31, 2024